RIOT

#1124
Riot Platforms, Inc. - Common Stock
17.7 9 USD
-0.06%
Market Price
Sektor: Finanzen
Basis: USD
Gewinnwährung: USD
Tagesspanne
17.74
18.18
Jahresspanne
11.50
30.32
Tagesänderung
-6.37%
Monatliche Änderung
-9.33%
6 month change
+14.41%
Jahresänderung
+33.76%
Vorheriger Schlusskurs
19.0 0
Open
18.0 9
Tief
17.7 4
Hoch
18.1 8
Volumen
5 722
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Riot Platforms, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Riot Platforms, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Riot Platforms, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Riot Platforms, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Riot Platforms, Inc. current report, Q1 FY2026
8-K

Riot Platforms, Inc. current report, Q2 FY2007

Full document

SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)

Business Context and Reporting Period

This Form 8-K Current Report was filed by AspenBio Pharma, Inc. on May 4, 2007, covering events occurring on May 3, 2007. The filing discloses the entry into a material definitive agreement to settle ongoing litigation with Strategic Growth International, Inc. (SGI). Note: The request metadata referenced "Riot Platforms, Inc." and a 2007 date, but the provided source text explicitly identifies the registrant as AspenBio Pharma, Inc.

Key Financial Metrics

The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial figures disclosed relate to the settlement:

  • Settlement Payment: $8,000 cash payment by the Company.
  • Claim Amount Settled: Approximately $47,000 sought by SGI.
  • Financial Impact: The Company anticipates recognizing debt reduction income due to the settlement of the payable. No other income or expense is expected from this agreement.

Material Changes and Agreements

The primary material change is the resolution of litigation with SGI. Key terms of the settlement include:

  • Resolution of a dispute where SGI sought approximately $47,000.
  • The Company agreed to pay $8,000 to settle the matter.
  • The Company agreed to discontinue its attempt to cancel 798,000 stock options issuable under a January 2004 consulting agreement with SGI.

Outlook, Risks, and Contingencies

Management commentary indicates that aside from the debt reduction income, the settlement will not result in additional income or expense. The filing resolves a legal contingency regarding the consulting agreement and the associated financial claim. No forward-looking guidance or new risk factors were disclosed in this specific report.

Investor Verification Checklist

  • Verify the exact amount of debt reduction income to be recognized in the next financial reporting period.
  • Confirm the status and valuation of the 798,000 stock options that were retained under the settlement.
  • Review the full text of the Stock Option Agreement (Exhibit 4.1) for any remaining obligations to SGI.
  • Check subsequent filings for the actual recording of the settlement income and cash outflow.

Nachrichten